HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

K Hirashima Selected Research

Esophageal Squamous Cell Carcinoma

2/2012Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


K Hirashima Research Topics

Disease

2Neoplasms (Cancer)
02/2012 - 07/2001
2Leukemia
12/2000 - 03/2000
1Esophageal Squamous Cell Carcinoma
02/2012
1Type 2 von Willebrand Disease
05/2008
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/2008
1Carcinogenesis
03/2008
1Lymphoma (Lymphomas)
03/2002
1Febrile Neutropenia
07/2001
1Multiple Myeloma
07/2001
1Neutropenia
07/2001
1Lymphoid Leukemia
03/2000
1B-Cell Leukemia (Leukemia, B Cell)
03/2000

Drug/Important Bio-Agent (IBA)

2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
12/2000 - 03/2000
1Therapeutic UsesIBA
02/2012
1TOR Serine-Threonine KinasesIBA
02/2012
1Pharmaceutical PreparationsIBA
02/2012
1EverolimusFDA Link
02/2012
1von Willebrand FactorIBA
05/2008
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
03/2008
1Interleukin-2 Receptors (IL 2 Receptor)IBA
03/2002
1Thymidine KinaseIBA
03/2002
1LenograstimIBA
07/2001
1ranimustineIBA
07/2001
1EndonucleasesIBA
12/2000
1Messenger RNA (mRNA)IBA
03/2000
1Granulocyte Colony-Stimulating Factor Receptors (G-CSF Receptor)IBA
03/2000
1Surface Antigens (Surface Antigen)IBA
03/2000
1AntigensIBA
03/2000

Therapy/Procedure

2Therapeutics
03/2002 - 07/2001
1Drug Therapy (Chemotherapy)
07/2001